Progressive Pericardial Effusions (PEF) in Patients With Pulmonary Arterial Hypertension (PAH) Taking Sotatercept-Association With Pre-Existing Pericardial Effusion

Authors

Hilamber Subba, Maine Medical Center Tufts University School of Medicine Portland Maine USA.
Tapan H. Mehta, Department of Internal Medicine Maine Medical Center Portland Maine USA.
John Gilboy, Maine Medical Center Tufts University School of Medicine Portland Maine USA.
Jacob Gelman, Maine Medical Center Tufts University School of Medicine Portland Maine USA.
Rachel Cutting, Department of Internal Medicine Maine Medical Center Portland Maine USA.
Kellie Ramsdell, Cardiovascular Medicine Maine Medical Center Portland Maine USA.
Heidi Roy, Cardiovascular Medicine Maine Medical Center Portland Maine USA.
Joel A. Wirth, Maine Medical Center Tufts University School of Medicine Portland Maine USA.

Document Type

Letter to the Editor

Publication Date

11-26-2025

Institution/Department

Pulmonary and Critical Care Medicine; Cardiology

Journal Title

Pulmonary circulation

Abstract

Pericardial effusion (PEF) in PAH may be a marker of worsening disease or associated with autoimmune conditions. Sotatercept was not initially reported as associated with the development or progression of PEF. We describe PAH patients taking sotatercept who were found to have new or worsening PEF and examine associated comorbidities.

ISSN

2045-8932

Comments

Jacob Gelman- Resident

First Page

e70215

Recommended Citation

Subba, Hilamber; Mehta, Tapan H.; Gilboy, John; Gelman, Jacob; Cutting, Rachel; Ramsdell, Kellie; Roy, Heidi; and Wirth, Joel A., "Progressive Pericardial Effusions (PEF) in Patients With Pulmonary Arterial Hypertension (PAH) Taking Sotatercept-Association With Pre-Existing Pericardial Effusion" (2025). MaineHealth Maine Medical Center. 4230.
https://knowledgeconnection.mainehealth.org/mmc/4230